Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marinus Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Marinus Pharmaceuticals was founded to take ganaxolone, a problematic compound for which tantalizing human efficacy data already exists and reformulate it to overcome the pharmacokinetic and cost problems holding it back. In just two years since in-licensing it, Marinus has succeeded in reformulating the drug and putting it back into clinical testing for two epilepsy indications with hopes of building a multi-indication franchise around it.

You may also be interested in...



Start-Up Previews (4/07)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.

Start-Up Previews (4/07)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.

RHEI Pharmaceuticals Inc.

Specialty pharma RHEI Pharmaceuticals' mission is to in-license China rights to partners' approved drugs or late-stage candidates, shepherd them through regulatory approval, and launch them in the China marketplace.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel